Key Question Answer

Global Market Outlook

In-depth analysis of global and regional trends

Analyze and identify the major players in the market, their market share, key developments, etc.

To understand the capability of the major players based on products offered, financials, and strategies.

Identify disrupting products, companies, and trends.

To identify opportunities in the market.

Analyze the regional penetration of players, products, and services in the market.

Comparison of major players financial performance.

Evaluate strategies adopted by major players.

Recommendations

Anti-inflammatory Drugs Market

Market for anti-inflammatory medications was estimated to be worth US$ XX billion globally in 2023 and is projected to increase at a compound annual growth rate (CAGR) of XX% from 2024 to 2033, reaching approximately US$ XX billion. The primary objectives of pain management, better function, and increased health-related quality of life for patients are what are primarily driving the market expansion for anti-inflammatory medications. NSAIDs, or nonsteroidal anti-inflammatory medicines, are the most often recommended drugs for treating musculoskeletal pain. Their clinical usefulness in reducing mild-to-moderate pain is crucial, as it strikes a balance between effectiveness and possible adverse effects. This well-rounded strategy highlights the rising need for anti-inflammatory medications, which is being driven by the growing focus on improving patient outcomes through efficient pain management techniques.

Market Overview
Because anti-inflammatory medications restrict the chemicals in the body that cause swelling, pain, and redness, they can lessen inflammation, which is why the market for these medications is expanding quickly. Inhibiting cyclooxygenase (COX), an enzyme that produces prostaglandins (PGs) linked to inflammation, is how these medications, especially non-steroidal anti-inflammatory medicines (NSAIDs), work to treat inflammation. COX-2 causes PGs that contribute to inflammation-related discomfort and oedema, whereas COX-1 produces PGs that shield the kidney and stomach. NSAIDs are commonly used to treat a variety of unpleasant diseases, but even with short-term use, there is reason for care when prescribing them. Unless otherwise advised, paracetamol is favoured over NSAIDs in primary care settings. Naproxen or ibuprofen are advised as first-line therapies, but only at the lowest effective dose and length of time feasible. This market overview emphasises how anti-inflammatory medications are widely used and carefully managed in healthcare practices, highlighting their important role in therapeutic strategies globally.

Key Insights

•    North America has captured the highest market share.
•    By drug class, the anti-inflammatory biologics segment holds the largest share of the market.
•    By application, the autoimmune inflammatory illness segment dominated the market.
•    By End-user, the hospital pharmacy segment is expected to grow at a significant rate during the forecast period.

Regional Stance
Due in large part to the widespread usage of nonsteroidal anti-inflammatory medications (NSAIDs), the North American region dominates the market for anti-inflammatory drugs. With over 30 million estimated daily users and 60% of the analgesic market in the United States alone, NSAIDs are among the most widely used medication classes in the world. About 20 distinct NSAIDs are marketed in the United States and can be purchased over-the-counter (OTC) or with a prescription. About 29% of people in Canada take prescription NSAIDs, and many more use over-the-counter versions. In Canada, NSAIDs are frequently prescribed by physiotherapists as part of all-encompassing treatment regimens for patients with musculoskeletal disorders or injuries in order to control pain and inflammation. Because they are the first point of contact for patients, Canadian physiotherapists are in a unique position to provide advice on the use of NSAIDs. This is due in large part to the fact that NSAIDs are widely used in physiotherapy practices and are therefore highly visible throughout the country's healthcare system.
• In March 2023, Sandoz received US FDA approval for biosimilar Hyrimoz (adalimumab-adaz) high-concentration formulation

Market for anti-inflammatory medications is expanding rapidly in the Asia-Pacific area due to a number of factors, including the region's exponential population expansion, growing healthcare costs, and an increase in the incidence of infectious, chronic, and lifestyle-related disorders. Comprehensive data on NSAID utilisation patterns, particularly at tertiary care centres, is conspicuously lacking in India, particularly in regions such as Chhattisgarh. Closing this gap is essential to encouraging more sane prescription practices. In order to compare the NSAID drug use trends at a recently opened tertiary care teaching hospital in Raipur, Chhattisgarh, with standardised WHO prescribing indicators, a study was conducted. This program aims to improve healthcare delivery and prescriber practices in line with the changing needs of the Asia-Pacific anti-inflammatory drug market.

Report Highlights
By Drug Class
According to pharmaceutical class, the anti-inflammatory medicine market is divided into corticosteroids, non-steroidal anti-inflammatory medications (NSAIDs), and anti-inflammatory biologics. The anti-inflammatory biologics industry holds the highest share of these. Unlike traditional disease-modifying antirheumatic medications (DMARDs), which generally inhibit the immune system, these biologic medicines are specially made to treat rheumatological illnesses by targeting proteins that cause inflammation.. Biologics can prevent joint and organ damage in disorders like arthritis by having strong anti-inflammatory effects, but they also come with hazards like respiratory infections and non-infectious pulmonary diseases. This section highlights the increasing importance of tailored treatments in the treatment of long-term inflammatory diseases, which is in line with advances in precision medicine in the pharmaceutical sector.

By Application
Based on application, the pharmaceutical market is divided into categories such as respiratory ailments, autoimmune inflammatory disorders, and other diseases. Psoriasis and rheumatoid arthritis are two examples of autoimmune inflammatory diseases that are predicted to generate the most revenue among them. The goal of medications for these illnesses is to maintain organ function while controlling the immune system. For example, anti-TNF drugs target tumour necrosis factor (TNF), a protein that causes inflammation, and are used to treat psoriasis and autoimmune arthritis. Nonsteroidal anti-inflammatory medicines (NSAIDs) are used to treat these conditions by reducing pain, swelling, and stiffness. This sector demonstrates the sizeable market opportunity in treating inflammatory autoimmune diseases, which is being driven by advances in therapeutic strategies that strike a balance between immune modulation and organ support.
market for respiratory illnesses is expected to rise steadily throughout the forecast period due to an increase in corticosteroid inhalation among COPD patients. Anti-inflammatory drugs are essential in lowering mucus formation, oedema, and inflammation of the airways, which in turn reduces the sensitivity of the airways to stimuli. Some of these drugs relieve symptoms right away, while others need to be used for an extended period of time each day in order to completely control symptoms. Effective COPD management depends on anti-inflammatories, especially corticosteroids, which reduce symptoms, improve airflow, and lessen airway damage. This application insight highlights the important therapeutic advantages of anti-inflammatory medications in improving respiratory health outcomes and meeting patients' changing needs who suffer from long-term respiratory diseases.

By Distribution Channel
Hospital pharmacy industry has become a leader in the anti-inflammatory medicine market's distribution channels, which include retail pharmacies, online pharmacies, and hospital pharmacies. The expanding prevalence of inflammatory disorders, favourable health reimbursement systems, and the growing need for anti-inflammatory pharmaceuticals are the reasons behind this. Compared to other drug classes, non-steroidal anti-inflammatory medicines (NSAIDs), a significant category in this market, have been linked to an increased rate of emergency hospital admissions because of adverse drug responsess. Making sure patients receive precise instructions on how to take NSAIDs safely and effectively is one way to address this issue. Healthcare professionals can reduce the dangers connected with these drugs and improve patient outcomes in the treatment of inflammatory illnesses by encouraging patient education on the appropriate use of NSAIDs.

Due to rising demand for over-the-counter (OTC) medications such as diclofenac and ibuprofen, as well as increasing availability of OTC medications, the market for OTC medicines is expected to develop. Non-steroidal anti-inflammatory drugs (NSAIDs) including aspirin, ibuprofen (Advil, Motrin), and naproxen (Aleve, Naprosyn) are examples of over-the-counter medications that are readily available without a prescription. These over-the-counter drugs are quite good at lowering fever, reducing swelling, and relieving discomfort. OTC anti-inflammatories are widely used and adopted by customers seeking fast relief from common diseases, largely due to their accessibility and convenience. The aforementioned trend highlights the crucial function of retail pharmacies and additional distribution channels in enabling customers to obtain necessary over-the-counter drugs for the treatment of inflammatory ailments.

Market Dynamics
Driver
Clinical Efficacy of Anti-inflammatory Drugs
The market for anti-inflammatory medications is mostly driven by the clinical efficacy of non-aspirin NSAIDs in the treatment of acute pain. These effects are similar to those of opioid starting doses, but they have a different ceiling dose impact. When it comes to analgesic relief, nonsteroidal anti-inflammatory drugs (NSAIDs) don't have the ceiling effect that comes with opioids, which carry the risk of addiction and overdose. Research on individuals with arthritis has demonstrated the superiority of non-steroidal anti-inflammatory drugs (NSAIDs) such celecoxib and diclofenac over acetaminophen in decreasing pain, swelling in the joints, stiffness in the morning, and enhancing mobility. These results highlight the increasing use of NSAIDs in clinical settings, which is fuelling the growth of the anti-inflammatory drug industry and improving patient outcomes and comfort in acute pain treatment situations.

Restraints
Risk of Adverse Effects
Likelihood for major side effects such cardiovascular events, gastrointestinal issues, renal failure, and hypersensitivity reactions tempers the broad usage of NSAIDs. Even while the danger for each patient is relatively low, the cumulative usage of NSAIDs throughout populations raises the overall probability of adverse effects. This limits the market expansion for anti-inflammatory drugs by requiring a thorough assessment of each patient's risk factors prior to writing an NSAID prescription. When using NSAIDs in clinical practice, healthcare professionals need to weigh the risks and advantages of each in order to ensure patient safety and regulatory compliance.

Opportunities
Advancements in Targeted Drug Delivery
Improved therapeutic efficacy in the treatment and prevention of inflammatory illnesses is promised by the creation of innovative disease-targeted medication delivery techniques. With their emphasis on particular molecular pathways and reduction of systemic side effects, these developments present significant prospects for the anti-inflammatory drug market to flourish. The creation of novel treatments that enhance patient care and treatment outcomes is facilitated by forward-thinking research endeavours focused on comprehending the molecular mechanisms underlying inflammation, which in turn propels the growth of the anti-inflammatory drug industry.

• In March 2024, Avalo secured a novel anti-inflammatory drug through the AlmataBio buyout

Recent Developments

•    In April 2024, Alvotech and Teva announced the US FDA approval of SELARSDI (ustekinumab-aekn), a biosimilar to Stelara (ustekinumab)
•    In June 2024, EpiEndo and AlveoliX provided an update on their partnership aimed at pioneering ulcerative colitis treatment
•    In March 2022, Pfizer completed the acquisition of Arena Pharmaceuticals

Key Players in the Anti-inflammatory Drugs Market
Eli Lily and Company
AstraZeneca PLC, Amgen Inc.
F. Hoffman, Abbvie, Inc.
Johnson & Johnson
GlaxoSmithKline
Merck & CO., Inc.
Novartis
Pfizer, Inc.
La Roche AG
Ferring Pharmaceuticals
Bioventus
Zimmer Biomet Holdings, Inc.
Flexion Therapeutics, Inc

Market Segmentation
By Drug Class
Anti-inflammatory Biologics
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids

By Indication
Arthritis
Rheumatoid Arthritis
Osteoarthritis
Ankylosing Spondylitis
Psoriatic Arthritis
Gout
Respiratory diseases
Asthma
Chronic obstructive pulmonary disease (COPD)
Multiple sclerosis
Psoriasis
Inflammatory bowel disease
Crohn's Disease
Ulcerative Colitis
Other inflammatory diseases

By Application
Autoimmune
Inflammatory Diseases (Rheumatoid Arthritis Psoriasis)
Respiratory Diseases
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
By Geography
North America
U.S.
Canada
Europe
Germany
France
United Kingdom
Rest of Europe
Asia Pacific
China
Japan
India
Southeast Asia
Rest of Asia Pacific
Latin America
Brazil
Rest of Latin America
Middle East & Africa (MEA)
GCC
North Africa
South Africa
Rest of Middle East & Africa

Choose License Type

Single User

$3999
Multi User

$5550
Enterprise User

$6999

Request Sample Ask For Customization Check Discount Speak TO Analyst Inquiry Before Buying

Our Reports Look Like This

HAVE A QUESTION

will help you find what you are looking for:

+91 7821962914

Anti-inflammatory Drugs Market

Report ID : 582

Category : Pharmaceuticals

No Of Pages : 170

Published on: July 2024

Status: Published

Format :

Choose License Type

Our Reports Look Like This

HAVE A QUESTION

Related Reports

Published on July 2025

$ 3999

Published on June 2025

$ 3999

Published on June 2025

$ 3999

Published on June 2025

$ 3999

Published on June 2025

$ 3999

Published on June 2025

$ 3999

Recent Reports

Published on July 2024

$ 3999

Published on April 2024

$ 3999

Published on April 2024

$ 3999

Published on November 2024

$ 3999

Published on June 2025

$ 3999

Published on March 2025

$ 3999

Free Sample Request

Alternative Text

Subscribe to Newsletter